Validated

Sep 2022 - ViroVet vaccine approach validated by funding for human health firm

Blocking ASF

Sep 2021 - ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV infected pigs

Promising Vaccine

Jul 2020 - Virologists at the Rega Institute at KU Leuven (Belgium) have developed a vaccine candidate that protects hamsters from infection with the SARS-CoV-2 coronavirus.

African Swine Fever

May 2019 - Belgian biotechnology company ViroVet will partner with Researchers at The Pirbright Institute to develop the first antiviral drugs that act against African swine fever (ASF).

Awarded

Jan 2018 - ViroVet is proud to announce that it has been presented with the best start-up of the year accolade for the second time. Two years ago, the company was awarded for its concept and ideas, this time the jury bestowed the company for its progress and its ability to raise capital.

Chairman

Jan 2017 - ViroVet is proud to announce that Dr George Gunn joined its board of directors. Dr Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis until early 2015.Before joining Novartis in 2003, he worked with the UK's Ministry of Agriculture, Fisheries and Food in the 1970s and 1980s and held various functions in the Animal Health Industry from head of Janssen Animal Health in the UK in 1996 up to president of Pharmacia Animal Health in the early 2000s. He received the Animal Pharm Lifetime Achievement Award in January 2017.

Series C

Jun 2022 - ViroVet is proud to announce that it has successfully concluded its series C financing round, bringing the total amount raised since its start close to 20 million euros.

JEV Vaccine

Mar 2021 - ViroVet successful with second swine vaccine based on new vaccine technology, Rega Institute assesses development of human version.

Series B

May 2020 - Seventure joins ViroVet in Series B funding. The financing will be used to further develop and launch its veterinary product portfolio. The investment round was led by Seventure Partners with participations from the existing shareholders.

Winners

Oct 2018 - ViroVet has won the Pre-Slush pitching competition organised by PwC. The finalists of the pitching competition had just 3 minutes each to convince the jury and the audience about the innovative aspects and scalability of their business concept and/or technology. The winner goes to Slush in Helsinki.

New investor

Oct 2017 - ViroVet, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has attracted Capricorn Venture Partners to conclude the second closing of its series A financing round, raising another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.

Capital

Dec 2016 - ViroVetis proud to announce that it has successfully concluded the first closing of its series A financing round, raising 5 million euro. The financing will be used to further develop and launch its veterinary product portfolio. The investment was led by PMV (through Biotech Fund Flanders) and the Agri Investment Fund, with participations from the Gemma Frisius Fund KU Leuven, Vives II and Aratana Therapeutics NV.

JEV-PLLAV works

Dec 2021 - ViroVet's PLLAV vaccine against Japanese encephalitis (JE) provides strong protection against infection.

PRRS Vaccine

Oct 2020 - ViroVet successfully confirmed the efficacy of its PRRS vaccine based on the PLLAV or plasmid-launched live attenuated virus technology

COVID19

Mar 2020 - Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing in Belgium.

Granted

Sep 2018 - ViroVet announced today that it has received a 590k€ grant from Flanders Innovation & Entrepreneurship (VLAIO) to assess the potential of its PLLAV-vaccination technology in poultry and large ruminants.

GALVmed

May 2017 - ViroVet, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce a collaboration with GALVmed. Under the collaboration, ViroVet will extend its vaccine pipeline to include novel vaccines for small ruminants.

Awarded

Jan 2016 - By Animal Pharm News: "The accolade of best start-up company for 2015 went to ViroVet. The Leuven-based company is a spin-out from US pet pharmaceutical developer Aratana Therapeutics. ViroVet is one of the only young veterinary medicine companies developing molecules for large unmet needs in livestock."